Key Takeaways MRKR stock rose 114% in three months driven by strong phase I APOLLO data for its lead T-cell therapy MT-601.MT-601 delivered ~66% response in NHL and 78% in Hodgkin Lymphoma with durable responses.MRKR advanced MT-601 to dose expansion, secured funding and manufacturing support & expects more data in 1H26.Marker Therapeutics’ (MRKR) shares have surged approximately 114% over the past three months, driven by strong momentum surrounding its early-stage lead candidate, MT-601, which has boosted ...